Promega, E9312, FuGENE® SI Transfection Reagent

Superior Knockdown Efficiency
FuGENE® SI outperforms Lipofectamine™ RNAiMAX in siRNA knockdown efficiency. HEK293-GFP and NIH3T3-GFP cell lines (Cell Biolabs) were seeded in 96-well plates according to user guides and subsequently transfected with 0.2, 1.0 or 5pmol of GFP targeting siRNA or negative control (Dharmacon™, Horizon) along with 0.3µl of FuGENE® SI Transfection Reagent or 0.3µl of Lipofectamine™ RNAiMAX (Life Technologies). Cells were then analyzed via flow cytometry 48 hours post-transfection to measure % knockdown of GFP and total cell viability. Graphs show the superior knockdown performance of FuGENE® SI versus Lipofectamine™ RNAiMAX in HEK293 and NIH3T3 cells.
FuGENE® SI outperforms Lipofectamine™ RNAiMAX in siRNA knockdown efficiency, as confirmed by Western blot. Human MDA-MB-468 cells were reverse-transfected in 6-well plates with 40pmol of the indicated targeting siRNAs or negative/positive control (Silencer® Select siRNA, Invitrogen) utilizing either 7.5µl of FuGENE® SI Transfection Reagent or 7.5µl of Lipofectamine™ RNAiMAX per well. The cells were collected 72 hours after transfection and analyzed via Western blot for expression of target genes STAT3 and CEBPB. The Western blot shown here demonstrates the robust, superior knockdown with FuGENE® SI as compared to the market leading competitor.